09th week of 2011 patent applcation highlights part 62 |
Patent application number | Title | Published |
20110053774 | SYNERGISTIC COMPOSITION AND METHOD OF USE - The present invention relates to a method to increase the effectiveness of an imidazolinone herbicide to suppress weedy forms of rice growth used with imidazolinone tolerant rice strains. This method involves applying an imidazolinone herbicide to imidazolinone tolerant rice strains in a field and applying either a propanil based herbicide or a thiobencarb herbicide to this rice crop, wherein the herbicide includes a synergistically effective amount a herbicidally inactive ingredient. The propanil based herbicide synergistically affects the activity of an imidazolinone herbicide by increasing the effectiveness of an imidazolinone herbicide used with the rice to suppress weedy forms of rice growth, such as red rice. | 2011-03-03 |
20110053775 | HERBICIDAL COMPOSITION AND METHOD OF USE THEREOF - The present invention relates to a method of controlling the growth of weeds, in particular, large crabgrass and white clover, using a herbicidal composition comprising mesotrione and a s-metolachlor. | 2011-03-03 |
20110053776 | BLENDS OF MICRO-ENCAPSULATED PESTICIDE FORMULATIONS - The present invention is directed to micro-encapsulated formulations of soil-active pest control and agricultural chemicals such as herbicides, insecticides, nematicides and fungicides (pesticides) that combine a strong initial activity and a longer residual activity in the soil than provided by current micro-encapsulated formulations. These formulations are prepared by combining two separate suspensions of microcapsules, containing one or more pesticides, which were separately prepared under differing conditions and therefore have significantly different chemical properties and field release rates. The present invention, in particular, is useful for the herbicide clomazone, alone or in combination with other herbicides. | 2011-03-03 |
20110053777 | Resistance to Acetolactate Synthase-Inhibiting Herbicides - Nucleotide sequences are disclosed that may be used to impart herbicide resistance to green plants. The sources of novel herbicide resistance were originally isolated in mutant | 2011-03-03 |
20110053778 | 2-(3-AMINOBENZOYL)-3-CYCLOPROPYL-3-OXOPROPANENITRILES AND THEIR USE AS HERBICIDES - 2-(3-Aminobenzoyl)-3-cyclopropyl-3-oxopropanenitriles of the formula (I) are described as herbicides. | 2011-03-03 |
20110053779 | 2-(3-ALKYLTHIOBENZOYL)CYCLOHEXANEDIONES AND THEIR USE AS HERBICIDES - 2-(3-Alkylthiobenzoyl)cyclohexanediones of the formula (I) are described as herbicides. | 2011-03-03 |
20110053780 | Cryogen Level Probe - A cryogen level probe, comprising a superconducting conductor ( | 2011-03-03 |
20110053781 | METHODS AND COMPOSITIONS FOR POLYPEPTIDE ENGINEERING - Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed. | 2011-03-03 |
20110053782 | NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY - The present invention relates to unnatural base pairs of Ds (a 5-amino-7-(2-thienyl)-3H-imidazo[4,5-b]pyridine-3-yl group) and a Pa derivative (a 2-nitro-1H-pyrrole-1-yl group bearing a substituent having a π-electron system attached at position 4) that can be replicated with high selectivity/high efficiency, and methods for replicating nucleic acids containing the unnatural base pairs. The present invention also relates to methods for incorporating an unnatural base bearing a functional substituent attached thereto into DNA by a nucleic acid replication reaction. The present invention also relates to methods for replicating and selectively collecting a nucleic acid containing an unnatural base pair from a nucleic acid pool. The present invention also relates to methods for determining a sequence of natural bases in the proximity of an unnatural base in DNA for achieving highly efficient and highly selective replication of a nucleic acid containing the unnatural base. | 2011-03-03 |
20110053783 | BIOACTIVE SURFACE FOR HEPATOCYTE-BASED APPLICATIONS - The invention provides a surface, wherein said surface comprises (i) a polymer substrate and (ii) sugar groups and peptide groups coupled to said substrate suitable for culturing hepatocytes. | 2011-03-03 |
20110053784 | Microfluidic Device and Methods of Using Same - A variety of elastomeric-based microfluidic devices and methods for using and manufacturing such devices are provided. Certain of the devices have arrays of reaction sites to facilitate high throughput analyses. Some devices also include reaction sites located at the end of blind channels at which reagents have been previously deposited during manufacture. The reagents become suspended once sample is introduced into the reaction site. The devices can be utilized with a variety of heating devices and thus can be used in a variety of analyses requiring temperature control, including thermocycling applications such as nucleic acid amplification reactions, genotyping and gene expression analyses. | 2011-03-03 |
20110053785 | SAMPLE PROCESSING DEVICES - Methods and devices for thermal processing of multiple samples at the same time are disclosed. The sample processing devices provide process arrays that include conduits useful in distributing sample materials to a group of process chambers located in fluid communication with the main conduits. The sample processing devices may include one or more of the following features in various combinations: deformable seals, process chambers connected to the main conduit by feeder conduits exiting the main conduit at offset locations, U-shaped loading chambers, and a combination of melt bonded and adhesively bonded areas. | 2011-03-03 |
20110053786 | HIGH THROUGHPUT SCREENING EMPLOYING COMBINATION OF DISPENSING WELL PLATE DEVICE AND ARRAY TAPE - High throughput screening is performed by directing an array tape ( | 2011-03-03 |
20110053787 | Compositions and Methods of Detecting Post-Stop Peptides - The present invention relates to novel methods and products for assessing the physiological status of a subject. More particularly, the invention relates to methods of assessing the presence, risk or stage of a cancer in a subject by identifying or measuring the levels of proteins that exhibits post-stop peptides in a sample from the subject. The invention is also suitable to assess the responsiveness of a subject to a treatment, as well as to screen candidate drugs and design novel therapies. The invention may be used in any mammalian subject, particularly in human subjects. | 2011-03-03 |
20110053788 | DETECTION OF TARGET ANALYTES USING PARTICLES AND ELECTRODES - The invention relates to the use of particles comprising binding ligands and electron transfer moieties (ETMs). Upon binding of a target analyte, a particle and a reporter composition are associated and transported to an electrode surface. The ETMs are then detected, allowing the presence or absence of the target analyte to be determined. | 2011-03-03 |
20110053789 | MIRCOARRAY METHODS - The present invention provides a method for identifying a microarray probe set capable of identifying a member of a group of related nucleotide sequences, the method comprising the steps of providing a candidate probe set comprising at least one probe capable of differentially hybridizing to two or more members of the group of related nucleotide sequences, testing reactivity of the probe set against two or more members of the group of related nucleotide sequences, and observing the degree of difference in the patterns of reactivity of the probe set for the two or more members of the group of related nucleotide sequences. | 2011-03-03 |
20110053790 | METHOD AND KIT FOR DETECTION OF MICROORGANISM - A live cell of microorganism in a test sample is detected by the following steps of: a) adding a cross-linker capable of cross-linking a DNA by irradiation with light having a wavelength of 350 nm to 700 nm to the test sample; b) irradiating the test sample to which the cross-linker is added with light having a wavelength of 350 nm to 700 nm; c) removing the cross-linker contained in the test sample irradiated with light; d) adding a medium to the test sample from which the cross-linker is removed and incubating the test sample; e) adding again the cross-linker capable of cross-linking a DNA by irradiation with light having a wavelength of 350 nm to 700 nm to the incubated test sample; f) irradiating the test sample to which the cross-linker is added with light having a wavelength of 350 nm to 700 nm; g) extracting a DNA from the test sample and amplifying a target region of the extracted DNA by a nucleic acid amplification method; and h) analyzing the amplified product. | 2011-03-03 |
20110053791 | METHOD FOR DETECTING OR DETERMINING ABNORMAL PRION PROTEIN ASSOCIATED WITH TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN BLOOD-DERIVED SPECIMEN OR BODY FLUID-DERIVED SPECIMEN - A pretreatment method of a specimen used for detecting or determining abnormal prion protein (PrPres) associated with transmissible spongiform encephalopathy (TSE), wherein
| 2011-03-03 |
20110053792 | MICROARRAY FOR EXPRESSION ANALYSIS OF CELLULAR GLYCOSYLATION MECHANISM - The present invention relates to a support onto which a set of probes is applied wherein the set comprises: (a) probes capable of specifically hybridising with nucleic acids encoding fucosyltransferases; (b) probes capable of specifically hybridising with nucleic acids encoding galactosyltransferases; (c) probes capable of specifically hybridising with nucleic acids encoding N-acetylglucosaminyltransferases; (d) probes capable of specifically hybridising with nucleic acids encoding N-acetylgalactosaminyltransferases; (e) probes capable of specifically hybridising with nucleic acids encoding sialyltransferases; (f) probes capable of specifically hybridising with nucleic acids encoding sugar sulfotransferases; (g) probes capable of specifically hybridising with nucleic acids encoding lectins; (h) probes capable of specifically hybridising with nucleic acids encoding selectins; (i) probes capable of specifically hybridising with nucleic acids encoding fucosidases; (j) probes capable of specifically hybridising with nucleic acids encoding neuraminidases (sialidases); (k) probes capable of specifically hybridising with nucleic acids encoding nucleotide sugar epimerases; (l) probes capable of specifically hybridising with nucleic acids encoding sugar kinases; (m) probes capable of specifically hybridising with nucleic acids encoding sugar epimerases; (n) probes capable of specifically hybridising with nucleic acids encoding sugar transporters; and (o) probes capable of specifically hybridising with nucleic acids encoding enzymes of the fucose or sialic acid metabolism. The invention further relates to a kit which comprises the probes of the invention and the use of the support or the kit of the invention for the quantitative determination of expression profiles in a sample obtained from a cell, a tissue or an organism. The present invention further relates to a diagnostic composition and the use of the set of probes of the invention for the preparation of diagnostic compositions or of a diagnostic apparatus for the diagnosis of tumours, inflammatory and/or neurological diseases. | 2011-03-03 |
20110053793 | METHODS AND PRODUCTS FOR IDENTIFYING STRAINS OF BACTERIA - Methods for identifying strains of bacteria, particularly methods for serotyping | 2011-03-03 |
20110053794 | NANOSTRUCTURED SUBSTRATES FOR SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) AND DETECTION OF BIOLOGICAL AND CHEMICAL ANALYTES BY ELECTRICAL DOUBLE LAYER (EDL) CAPACITANCE - Provided according to embodiments of the invention are nanostructured surfaces that include a substrate; and an array of metallic nanopillar islands on the substrate, wherein each metallic nanopillar island includes a metal base layer on the substrate and a plurality of metallic nanopillars on the metal base layer, and wherein portions of the substrate between adjacent metallic nanopillar islands are free of the metal base layer. Also provided according to some embodiments of the invention are nanostructured surfaces that include a non-conductive substrate; and at least one nanoelectrode defined within the non-conductive substrate, wherein the at least one nanoelectrode is sized and/or shaped to immobilize an analyte or a probe molecule. Also provided are apparatuses and methods for SERS and detection of analytes or biological binding by EDL capacitance. | 2011-03-03 |
20110053795 | Osmolyte Mixture for Protein Stabilization - An osmolyte composition comprising 4 M glycerol and 4M urea for stabilizing previously transient protein folding intermediates as long-lived stable forms. A method to search for other possible stabilizing osmolyte mixtures using a screening array is also provided. These additional osmolyte mixtures may complement or augment the successful 4M glycerol/4 M urea mixture. | 2011-03-03 |
20110053796 | MODIFIED STEFIN A SCAFFOLD PROTEINS - The invention provides novel scaffold proteins for the display of peptides such as peptide aptamers. The novel scaffold proteins are modifications of Stefin A or STM (a variant of Stefin A) and are useful as scaffold proteins and as display systems. | 2011-03-03 |
20110053797 | DEVICE AND METHOD FOR HANDLING MULTI-COMPONENT MIXTURE - Device and method for handling multi-component mixtures, comprising at least two not completely mixable fluid phases. The device comprises an arrangement of at least two high-pressure separators, being operatively connected each with a low-pressure separator. Each high-pressure separator comprises an outlet line for volatile gaseous constituents. Each low-pressure separator is operatively connected to a gas collecting container or shares at least one gas collecting container with a further low-pressure separator. At least one high-pressure separator has at least one outlet connection for gaseous constituents, being connected with a part to the analysis. The device is used in high-throughput research or in combinatory chemistry, preferably for the research of multi-component mixtures produced in experiments with catalyst, or in connection with high-pressure processes. | 2011-03-03 |
20110053798 | SYSTEM FOR MIXING FLUIDS BY COALESCENCE OF MULTIPLE EMULSIONS - System, including methods, apparatus, compositions, and kits, for the mixing of small volumes of fluid by coalescence of multiple emulsions. | 2011-03-03 |
20110053799 | METHOD OF PRODUCING MICROARRAY SUBSTRATE, RADIATION-SENSITIVE COMPOSITION, PARTITION OF MICROARRAY SUBSTRATE, METHOD OF PRODUCING BIOCHIP, AND BIOCHIP - A method is of producing a microarray substrate that includes a substrate, a partition that is formed on a surface of the substrate, and an area that is positioned over the substrate and defined by the partition. The method includes forming a first film on the substrate using a radiation-sensitive composition. The radiation-sensitive composition includes a coloring agent (A) including at least one of a violet pigment (a2) and a compound (a1) shown by a formula (1) in which each of R | 2011-03-03 |
20110053800 | METHOD OF MANUFACTURING PATTERNED SUBTRATE FOR CULTURING CELLS, PATTERNED SUBTRATE FOR CULTURING CELLS, PATTERNING METHOD OF CULTURING CELLS, AND PATTERNED CELL CHIP - The present invention relates to a method of manufacturing a patterned substrate for culturing cells, comprising the steps of: (1) preparing a substrate; (2) forming a first plasma polymer layer by integrating a first precursor material using a plasma on the substrate; (3) placing a shadow mask having a predetermined pattern on the first plasma polymer layer; and (4) forming a second patterned plasma polymer layer by integrating a second precursor material using a plasma. | 2011-03-03 |
20110053801 | Method for the Random Diversification of a Genetic Sequence While Preserving the Identity of Some Inner Segments of said Genetic Sequence - The invention relates to a very general method for the random diversification of a nucleotide sequence S by PCR while preserving the identity of some domains of said sequence S; the invention also relates to a bank of nucleotide sequence thus diversified, and to diversified proteins obtained by the expressions of the nucleotide sequences in an appropriate host. | 2011-03-03 |
20110053802 | CATEGORIZATION OF MICROBIAL COMMUNITIES - The present disclosure provides embodiments of a method for characterizing microbial populations. Exemplified by methods for characterizing microbiota in vaginal samples, the methods provided herein are widely applicable to the characterization of microbial communities. Also provided are probiotic regimens and methods for selecting appropriate probiotic regimens based on the normal vaginal microbiota of a subject. Reagents and kits for detecting normal vaginal microbiota and diagnosing pathogenic microorganisms in the vagina are also provided. | 2011-03-03 |
20110053803 | METHODS FOR CREATING ANTIBODY LIBRARIES - Methods and composition for the preparation of gene libraries of antibodies or parts of antibodies which contain the variable domains. For example, in certain aspects methods for providing polynucleotide library involving annealing and extending are described. Furthermore, the invention provides polynucleotide or antibody fragment libraries prepared by the methods. | 2011-03-03 |
20110053804 | Gene Signatures for the Prognosis of Cancer - The cytokine TGFβ, in the tumor microenvironment, primes cancer cells for metastasis to the lungs. TGFβ response status (TBRS) can be determined by comparing expression levels of a panel of genes from cancer cells to the expression levels of the same genes in epithelial cell lines before and after induction with TGFβ. A TGFβ gene response signature reveals a clinical association between TGFβ activity in primary estrogen receptor negative (ER−) tumors and risk of lung metastasis. Further, combining the gene signature of the present invention with the known lung metastasis signature (LMS) increases the predictive value of the LMS considerably. | 2011-03-03 |
20110053805 | THERMOCHEMICAL NANOLITHOGRAPHY COMPONENTS, SYSTEMS, AND METHODS - Improved nanolithography components, systems, and methods are described herein. The systems and methods generally employ a resistively heated atomic force microscope tip to thermally induce a chemical change in a surface. In addition, certain polymeric compositions are also disclosed. | 2011-03-03 |
20110053806 | INTEGRATED CARRIER FOR MICROFLUIDIC DEVICE - A carrier for holding a microfluidic device includes a substrate with a plurality of wells, each well defining a volume of between 0.1 μl and 100 μl; a plurality of channels within the substrate wherein each well is in fluid communication with at least one of the plurality of channels; and a receiving portion for receiving a microfluidic device and placing the microfluidic device in fluid communication with the plurality of wells. The carrier has a polymeric composition and/or an array of structural features that enhance its performance and compatibility with existing instrumentation. | 2011-03-03 |
20110053807 | METHODS TO CONTROL FLUID LOSS IN A WELL BORE - The invention discloses a method of controlling fluid loss from a subterranean formation of a well bore. In a first aspect, the method is done by providing a treatment fluid made of an aqueous fluid and a hydrophobic polymer; and introducing the treatment fluid into the wellbore. In a second aspect, the method is done by providing a treatment fluid made of water and a water soluble polymer; providing in the treatment fluid a fluid loss additive having a hydrophobic polymer; using the treatment fluid in a well bore of a subterranean formation; allowing the treatment fluid to establish a permeable filter cake with the water soluble polymer in at least a portion of the well bore; and allowing hydrophobic polymer to enter into the filter cake to reduce permeability of the filter cake. | 2011-03-03 |
20110053808 | Suspension Characteristics in Invert Emulsions - Among the methods provided is a method of drilling a subterranean well with an invert emulsion fluid comprising: providing an invert emulsion fluid formed by combining components that comprise: an oil-based continuous phase; an aqueous discontinuous phase; and a polar hydrophobic additive that comprises a polar hydrophobe, wherein the polar hydrophobic additive may substantially increases the yield point, the low-shear yield point, or both of the invert emulsion fluid relative to a fluid without a polar hydrophobic additive while limiting the change in the plastic viscosity to no more than about 35% of the change in the property with the largest increase; and placing the invert emulsion fluid in a subterranean formation. | 2011-03-03 |
20110053809 | DEGRADABLE NON-AQUEOUS GEL SYSTEMS - A method of treating a formation that includes exposing a region of the formation occupied by a hydrolysable gel to a hydrolyzing agent; and allowing sufficient time for the hydrolyzing agent to hydrolyze the gel. Various methods may also include the use of a swelling agent to allow for expansion of the gel. | 2011-03-03 |
20110053810 | Fluorosurfactants and Treatment Fluids for Reduction of Water Blocks, Oil Blocks, and/or Gas Condensates and Associated Methods - The present invention relates to fluids useful for subterranean operations, and more particularly, to fluorosurfactants useful for the reduction of water blocks, gas blocks, and/or gas condensates and their associated treatment fluids and methods. Provided is a method of treating a subterranean formation. The method may comprise contacting the subterranean formation with a fluorosurfactant. The fluorosurfactant may comprise an amine group, wherein the amine group comprises at least one substituent selected from the group consisting of a fluoroalkyl group, a fluoroalkenyl group, and combinations thereof, wherein the at least one substituent comprises about 3 carbons to about 22 carbons. Also provided are polymeric surfactants and treatment fluids that comprise fluorosurfactants. | 2011-03-03 |
20110053811 | METHODS FOR PREVENTING OR REMEDIATING XANTHAN DEPOSITION - Methods for remediation and/or prevention of polymer deposition on surfaces, in particular, on surfaces of drilling machinery and earth formations in the petroleum industry are described herein. Embodiments disclosed herein relate to a method of remediating xanthan deposition, the method including the steps of contacting xanthan deposition, including xanthan complexed with polyvalent metal ions, with a remediation fluid containing at least one chelating agent; and allowing the fluid to dissolve the xanthan deposition. Also disclosed is a method of preventing polymer deposition, including emplacing a wellbore fluid including a crosslinkable polymer and at least one chelating agent in a wellbore; wherein the at least one chelating agent complexes with polyvalent metal ions present in the wellbore. Also disclosed is an improved wellbore fluid including a base fluid; a polymer comprising chemical groups reactive to polyvalent metal ions found downhole; and at least one chelating agent; wherein the least one chelating agent complexes with polyvalent metal ions downhole. | 2011-03-03 |
20110053812 | Polymeric Additives for Enhancement of Treatment Fluids Comprising Viscoelastic Surfactants and Methods of Use - Polymeric additives used with viscoelastic surfactants, fluids comprising such additives and viscoelastic surfactants, and associated methods of use, are provided. In one embodiment, the methods comprise: providing a treatment fluid that comprises an aqueous base fluid, a viscoelastic surfactant, and an amphiphilic polymer, the amphiphilic polymer comprising a hydrophobic component, and a hydrophilic component comprising at least 15 monomer units; and introducing the treatment fluid into at least a portion of a subterranean formation. | 2011-03-03 |
20110053813 | METHODS TO REDUCE SETTLING RATE OF SOLIDS IN A TREATMENT FLUID - The invention discloses a method of treating a subterranean formation of a well bore: providing a treatment fluid made of: a fluid; a particulate material, and a viscosifier material; wherein the viscosifier material is inactive in a first state and is able to increase viscosity of the treatment fluid when in a second state; introducing the treatment fluid into the wellbore; and providing a trigger able to activate the viscosifier material from first state to second state. | 2011-03-03 |
20110053814 | Natural gas engine lubricating oil compositions - A lubricating oil composition is disclosed which comprises (a) a major amount of an oil of lubricating viscosity, (b) one or more phosphorus-containing anti-wear additives other than a zinc dithiophosphate, (c) one or more ashless dispersants, (d) one or more metal-containing detergents, and (e) one or more antioxidants, wherein the lubricating oil composition contains no more than about 0.03 weight percent of phosphorus, based on the total weight of the natural gas engine lubricating oil composition, and further wherein the lubricating oil composition is substantially free of any zinc compounds. | 2011-03-03 |
20110053815 | LUBRICANT COMPOSITION - The invention provides a lubricating oil composition comprising:
| 2011-03-03 |
20110053816 | LUBRICANT COMPOSITION AND CONTINUOUSLY VARIABLE TRANSMISSION - Provided is a lubricating oil composition containing a base oil which includes a mineral oil and/or a synthetic oil, and compounded therein, (A) at least one phosphorus-containing compound selected from phosphoric acid monoesters, phosphoric acid diesters and phosphorous acid monoesters, each having a C | 2011-03-03 |
20110053817 | MULTI-GRADE ENGINE OIL FORMULATIONS COMPRISING A BIO-DERIVED ESTER COMPONENT - The present invention is generally directed to the present invention provides for multi-grade engine oil formulations comprising a diester component, wherein the diester component comprises vicinal diester species, and wherein at least a portion of said diester component is bio-derived. Many such formulations of the present invention are expected to favorably compete with similar, existing formulations comprising synthetic esters, but such formulations are generally expected to meet or exceed such existing formulations in a number of areas including, but not limited to, economics, biodegradability, and/or toxicity. | 2011-03-03 |
20110053818 | CONDITIONING SHAMPOO COMPOSITION - Aqueous conditioning shampoo comprising cleansing surfactant and a conditioning gel network, the gel network comprising a particulate having a melting point above 70° C. and glyceryl monostearate. | 2011-03-03 |
20110053819 | Composition - The present invention relates to compositions comprising polyaspartic acid (PAS) derivatives and the use of said compositions in washing processes, especially in automatic dishwashing. | 2011-03-03 |
20110053820 | DETERGENT COMPOSITION - An automatic dishwashing detergent composition comprising by weight of the composition: | 2011-03-03 |
20110053821 | METHOD FOR REMOVING/PREVENTING REDEPOSITION OF PROTEIN SOILS - A method and composition is provided for removing protein soil and preventing redeposition of soils onto a surface. The composition includes between about 1% and about 90% by weight sugar, between about 1% and about 80% by weight alkalinity source and between about 1% and about 10% by weight surfactant component. The sugar may be a saccharide or a non-saccharide based sugar. The composition is substantially free of phosphorus-containing compounds and includes less than about 0.05% by weight alkali earth metal. | 2011-03-03 |
20110053822 | Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 2011-03-03 |
20110053823 | Colored Speckles - This invention relates to non-bleeding and quick color releasing colored speckles for use in granular laundry detergents and other consumer products. The speckles are comprised of a porous carrier, a releasing agent, and a coloring agent. | 2011-03-03 |
20110053824 | LIQUID DETERGENT COMPOSITION EXHIBITING ENHANCED ALPHA-AMYLASE ENZYME STABILITY - Embodiments of the present aqueous liquid or gel detergent composition comprise boric acid or a boron compound capable of forming boric acid in the composition, a polyhydroxy compound, calcium ions, water, and an α-amylase enzyme at least 80% homologous with the α-amylase enzyme of SEQ ID NO: 2. | 2011-03-03 |
20110053825 | Composition - A cleaning composition comprises a dispersion. The dispersion includes an acidic aqueous phase and a suspended particle. The particle is coated with an acid stable coating. | 2011-03-03 |
20110053826 | Process For Making A Cleaning Composition Employing Direct Incorporation Of Concentrated Surfactants - The proposed process of the present application passes a concentrated surfactant in a lamellar phase though a high-shear device diluting the concentrated surfactant in a lamellar phase to an isotropic phase without encountering the highly viscous middle phase. | 2011-03-03 |
20110053827 | INTRANASAL ADMINISTRATION - Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region. | 2011-03-03 |
20110053828 | Use of Urea-Adjuvated Polypeptides for Diagnosis, Prophylaxis and Therapy - The invention relates to a method for infiltration of polypeptides in cells. The invention further relates to the use of the cells and urea-adjuvated polypeptides for the diagnosis, treatment or prevention of diseases. The invention further relates to the detection of polypeptide-specific immune cells. | 2011-03-03 |
20110053829 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS - The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier complex. The present invention also provides methods of application and use of this inventive polymeric carrier and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment such diseases. | 2011-03-03 |
20110053830 | METHODS FOR TREATING SEPTIC SHOCK - Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a peptide is administered to a subject with septic shock, such as septic shock induced by an infection with gram negative bacteria. | 2011-03-03 |
20110053831 | COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL DISORDERS ASSOCIATED WITH THEREWITH - Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS. | 2011-03-03 |
20110053832 | NATURAL ANTIMICROBIAL COMPOSITION - Natural antimicrobials for foods, such as salad dressings and dairy products to target a broad spectrum of food emulsion spoilage microorganisms such as lactic acid bacteria and fungi such as general yeast and even acid-tolerant yeast (such as | 2011-03-03 |
20110053833 | SYNTHETIC PEPTIDES AND THEIR USE - At least one embodiment of the present invention relates to new peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars. | 2011-03-03 |
20110053834 | NOVEL ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF - The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of | 2011-03-03 |
20110053835 | ANTIMICROBIAL PEPTIDES DERIVED FROM CAP18 - The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally. | 2011-03-03 |
20110053836 | USE OF DEFENSINS AGAINST TUBERCULOSIS - The present invention relates to a method for killing or inhibiting cells of | 2011-03-03 |
20110053837 | Mineral-peptide chelates - The present invention provides a mineral-peptide chelate comprising a peptide consisting of 2˜18 amino acids and a mineral chelated to the peptide, wherein the peptide can be a hydrolysate obtained by hydrolyzing soybean or other protein materials with proteases, or a product obtained by hydrolyzing soybean or other protein material with proteases and fermentation. The mineral-peptide chelate of the present invention may further comprise a carrier which covers the peptide and the mineral which is chelated to the peptide. | 2011-03-03 |
20110053838 | PROCESS FOR SOLUBILIZING GLUCAGON-LIKE PEPTIDE 1 COMPOUNDS - Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution. | 2011-03-03 |
20110053839 | GLP-1 Derivatives II - The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue. | 2011-03-03 |
20110053840 | ALLELE AND ISOTOPE-SPECIFIC INTERVENTION ON MHC CLASS II MOLECULES ASSOCIATED WITH AUTOIMMUNE DISEASES BY MEANS OF PEPTIDES - The present invention relates to a peptide for the treatment or prophylaxis of an autoimmune disease, a nucleic acid molecule coding for said peptide, a pharmaceutical composition comprising the peptide and/or the nucleic acid molecule, and to a method for the treatment and/or prophylaxis of an autoimmune disease. | 2011-03-03 |
20110053841 | N-TERMINAL FGF VARIANTS HAVING INCREASED RECEPTOR SELECTIVITY AND USES THEREOF - The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof. | 2011-03-03 |
20110053842 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR - The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 2011-03-03 |
20110053843 | E-SELECTIN COMPOSITIONS AND USE THEREOF FOR INDUCING E-SELECTIN TOLERANCE - The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia. | 2011-03-03 |
20110053844 | LIQUID FORMULATION OF G-CSF CONJUGATE - The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies. | 2011-03-03 |
20110053845 | LOCALIZED VAGINAL DELIVERY WITHOUT DETRIMENTAL BLOOD LEVELS - The invention relates to a pharmaceutical composition for vaginal administration of a treating agent normally associated with undesired side effects at detrimental blood levels. The composition releases the treating agent at a rate to achieve local tissue concentrations without such detrimental blood levels by using a therapeutically effective amount of the treating agent and a bioadhesive, cross-linked water swellable, but water-insoluble polycarboxylic acid polymer. Using this composition and the method of treatment provides sufficient local levels of the drug to provide therapeutic efficacy, but avoids many untoward adverse events. The invention also relates to a pharmaceutical composition for use during menses that includes a treating agent and a bioadhesive, cross-linked water swellable, but water-insoluble polycarboxylic acid polymer. | 2011-03-03 |
20110053847 | METHODS OF TREATING VASODILATORY SHOCK - The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor. | 2011-03-03 |
20110053848 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 2011-03-03 |
20110053849 | REGULATION OF LITAF MODULATED CYTOKINE PRODUCTION BY A NOVEL P53 SHORT PEPTIDE - The present invention relates to a novel isolated and purified peptide of the sequence KQSQHMT [SEQ ID NO: 1], nucleic acid sequences encoding said peptide sequence and capable of expressing said sequence as an exogenous protein in a target cell; as well as methods for the reduction or inhibition of LITAF activity by transfecting the peptide KQSQHMT [SEQ ID NO: 1] or a nucleic acid capable of expressing said peptide, into a target cell. The present invention also relates to the use of the novel peptide (and corresponding nucleotide sequences) of the present invention for the regulation of cytokine expression in target cells. The present invention also relates to the use of the novel peptide (and corresponding nucleotide sequences) of the present invention for the regulation of inflammatory responses in mammals. | 2011-03-03 |
20110053850 | DOC1 COMPOSITIONS AND METHODS FOR TREATING CANCER - A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth. | 2011-03-03 |
20110053851 | HAEMOSTASIS-MODULATING COMPOSITIONS AND USES THEREFOR - This invention discloses the use of snake venom FV polypeptides in methods and compositions for preventing or reducing blood loss or bleeding during bleeding episodes. | 2011-03-03 |
20110053852 | USE OF PODOCAN PROTEIN IN TREATING CARDIOVASCULAR DISEASES - The present invention relates to compositions and methods for the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant vasculopathy, and pulmonary hypertension More particularly, the present invention relates to methods and pharmaceutical compositions for delivering podocan or podocan inhibitors to the arterial system of an animal, thus resulting in the down-regulation or up-regulation, respectively, of smooth muscle cell (SMC) functions such as SMC proliferation and migration Up-regulation of vascular smooth muscle cell proliferation and/or migration by podocan inhibition results in the treatment of vulnerable plaques, while down-regulation of vascular smooth muscle cell proliferation and/or migration via podocan delivery and/or up-regulation results in the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant or graft vasculopathy and pulmonary hypertension. | 2011-03-03 |
20110053853 | USE OF COPOLYMER 1 FOR TREATMENT OF MUSCULAR DYSTROPHY - The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the active agent, for use in treating a muscular dystrophy disease or disorder. | 2011-03-03 |
20110053854 | TREATMENT OF MUSCULAR DYSTROPHIES AND RELATED DISORDERS - The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. | 2011-03-03 |
20110053855 | Ex vivo cell stimulation - Provided herein is are methods for evaluating the biological activity and/or therapeutic potential of a glucan, comprising in one embodiment: co-culturing a first population of cells with a second population of cells, wherein the first population comprises cells capable of being stimulated by said glucan to produce and/or secrete cytokines and growth factors, and the second population comprises collagen-producing cells; contacting said co-cultured cells with the glucan and incubating for a period of time sufficient to induce the production of collagen from the collagen-producing cells; and determining the level of production of collagen from said collagen-producing cells, wherein the level of production of collagen is indicative of the biological activity and/or therapeutic potential of the glucan. | 2011-03-03 |
20110053856 | METABOLITE DERIVATIVES OF THE HDAC INHIBITOR FK228 - The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases. | 2011-03-03 |
20110053857 | YEAST CELLS EXPRESSING TAR DNA-BINDING PROTEIN 43 AND USES THEREFOR - Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis. | 2011-03-03 |
20110053858 | HETEROCYCLIC PEPTIDE KETOAMIDES - A novel class of peptide α-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA | 2011-03-03 |
20110053859 | METHODS TO REDUCE THE EFFECTS OF SLEEP DEPRIVATION - The invention provides methods of treating symptoms of sleep deprivation using a hypocretin agonist. The invention also provides methods of treating Parkinson's disease using a hypocretin agonist. | 2011-03-03 |
20110053860 | COX-2 function and wound healing - The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing. | 2011-03-03 |
20110053861 | COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-KB) SIRNA AND METHODS OF USE - The present invention provides siRNA nucleic acid molecules that inhibit NF-kappaB expression. Methods of using the nucleic acid molecules are also provided. | 2011-03-03 |
20110053862 | COMPOSITIONS COMPRISING SURVIVIN SIRNA AND METHODS OF USE THEREOF - The present invention provides siRNA nucleic acid molecules that inhibit survivin expression. Methods of using the nucleic acid molecules are also provided. | 2011-03-03 |
20110053863 | METHODS OF USING FLT3-LIGAND IN THE TREATMENT OF CANCER - Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation. | 2011-03-03 |
20110053864 | Compositions and methods for modulation of cell migration - A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an Å6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition variants. A method of treating a disease characterized by aberrant cell migration and/or invasion includes administering to a subject an effective amount of the peptide of SEQ ID NO:3 or an Å6 polypeptide to bind to a CD44 polypeptide and modulate signal transduction activity for a sufficient period of time to treat the disease. Other methods include using the peptide of SEQ ID NO:3 or an Å6 polypeptide for diagnosing, identifying a subpopulation of subjects responsive to treatment, and screening for compounds that bind a CD44 polypeptide. | 2011-03-03 |
20110053865 | AMINO ACID SEQUENCES DIRECTED AGAINST HETERODIMERIC CYTOKINES AND/OR THEIR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME - The present invention relates to amino acid sequences that are directed against (at defined herein) heterodimeric cytokines and/or their receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consists of one or more such amino acid sequences ( also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as “nucleic acids of the invention” or “nucleotides sequences of the invention”); to methods for preparing such amino acid sequences and polypeptides; to hose cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that complete such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein. | 2011-03-03 |
20110053866 | PHARMACEUTICAL COMPOSITIONS - The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder. | 2011-03-03 |
20110053867 | L-SUGAR COLON CLEANSING AGENT AND USES THEREOF - Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing. | 2011-03-03 |
20110053868 | L-SUGAR COLON CLEANSING AGENT AND USES THEREOF - Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing. | 2011-03-03 |
20110053869 | METHODS AND COMPOSITIONS FOR INHIBITING PROGRESSION TO CHRONIC CARDIAC FAILURE - The present invention is provides methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and/or severe anemia of chronic disease, by administration of one or more rate-limiting precursors to the synthesis of ATP. In one embodiment the ATP precursor is a pentose selected from one or more of ribose, D-ribose, ribulose, xylitol, xylulose, and a 5-carbon precursor of ribose. | 2011-03-03 |
20110053870 | USE OF ISOTHIOCYANATE DERIVATIVES AS ANTI-MYELOMA AGENTS - The invention concerns the use of glucomoringin and of its des-thio-glucoside having the following formulae (I, II): for the preparation of a medicament for the treatment of myeloma. | 2011-03-03 |
20110053871 | METHODS OF REGULATING ACTIN CYTOSKELETAL REARRANGEMENT AND INTERCELLULAR GAP FORMATION - Methods are described for preventing or reducing cytoskeletal rearrangement and intercellular gap formation by contacting cells with an aminoalkyl glucosaminide phosphate. In particular, the disclosed methods can be used to prevent or reduce actin cytoskeletal rearrangement and/or intracellular gap formation related to ischemic or ischemia-reperfusion events and to prevent or alleviate diseases or conditions related to increased actin cytoskeletal rearrangement. | 2011-03-03 |
20110053872 | Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy. | 2011-03-03 |
20110053873 | HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds. | 2011-03-03 |
20110053874 | USE OF FLAVONOIDE COMPOUNDS FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC OR INFLAMMATORY HEART AND CARDIOVASCULAR DISEASES - The present invention relates to the use of flavonoid compounds, particularly quercetin-3-O-β-D-glucuronide and kaempferol-3-O-β-D-glucuronide and their glucosides, for preventing diseases of the heart. Red vine leaf extract has proved a particularly advantageous source of the flavonoid compounds in question. | 2011-03-03 |